ストックスクリーナーアプリを入手
0.791
3.31%
-0.0271
アフターアワーズ：
.78
-0.011
-1.39%
Hoth Therapeutics Inc (HOTH) 最新ニュース
Hoth Therapeutics shares hold buy as study shows cancer treatment promise - Investing.com
Hoth Therapeutics Receives Notification from Nasdaq Due to Minimum Bid Price Non-Compliance - Defense World
Hoth Therapeutics faces Nasdaq delisting over stock price By Investing.com - Investing.com Australia
Hoth Therapeutics faces Nasdaq delisting over stock price - Investing.com
Hoth Therapeutics reports stable tumor growth in study By Investing.com - Investing.com Canada
Hoth Therapeutics Up 34% on Favorable Early Data for Preclinical Study of Cancer Drug - MarketWatch
Hoth Therapeutics reports stable tumor growth in study - Investing.com
Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study - PR Newswire
Top investors say Hoth Therapeutics Inc (HOTH) ticks everything they need - SETE News
Hoth Therapeutics Inc [HOTH] Is Currently 8.11 above its 200 Period Moving Avg: What Does This Mean? - The DBT News
Hoth Therapeutics secures patent, analyst maintains steady target - Investing.com
Hoth Therapeutics secures patent, analyst maintains steady target By Investing.com - Investing.com UK
Hoth Therapeutics secures US patent for Alzheimer's drug By Investing.com - Investing.com Australia
HOTH’s Stock Market Adventure: -43.06% YTD Growth Amidst Volatility - The InvestChronicle
Hoth Therapeutics secures US patent for Alzheimer's drug - Investing.com India
Financial Metrics Check: Hoth Therapeutics Inc (HOTH)’s Ratios for Trailing Twelve Months - The Dwinnex
Hoth Shares Rise After Alzheimer's Treatment Gets Patent - MarketWatch
Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway - PR Newswire
Benchmark keeps Speculative Buy rating on Hoth shares on robust pipeline By Investing.com - Investing.com Canada
Benchmark keeps Speculative Buy rating on Hoth shares on robust pipeline - Investing.com
Hoth Therapeutics, Wise Systems Partner To Leverage AI For Drug Discovery - Contract Pharma
Micro Cap Already Off To The Races At The Bell - MSN
Hoth Therapeutics, Inc. (NASDAQ:HOTH) Sees Significant Increase in Short Interest - Defense World
EGFR Inhibitors-Induced Skin Disorders Market Growth - openPR
Buy Honasa Consumer, target price Rs 530: JM Financial - The Economic Times
Examining the Potential Price Growth of Holley Inc (HLLY) - Knox Daily
Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 4% - MarketBeat
Harrow Inc (HROW) Becoming More Attractive for Investors - Knox Daily
Davidson Kempner Capital Management LP Invests $3.21 Million in Loar Holdings, LLC (NYSE:LOAR) - Defense World
Why Investors Shouldn't Be Surprised By THOR Industries, Inc.'s (NYSE:THO) P/E - Simply Wall St
Lombard Odier Asset Management USA Corp Invests $786,000 in Hilton Grand Vacations Inc. (NYSE:HGV) - Defense World
THG Plunges 24% ATO amid Internal Frauds by Subsidiaries - KAOHOON INTERNATIONAL
Holley Inc. (NYSE:HLLY) Shares Sold by Kayne Anderson Rudnick Investment Management LLC - Defense World
Capstone Triton Financial Group LLC Has $707,000 Stock Position in Honeywell International Inc. (NASDAQ:HON) - Defense World
Hoth Therapeutics (NASDAQ:HOTH) Trading Down 3% - Defense World
Highbridge Capital Management LLC Purchases Shares of 630,114 HashiCorp, Inc. (NASDAQ:HCP) - MarketBeat
Haoxi Health Technology Down 75% After $12M Offering - MarketWatch
The time has not yet come to remove your chips from the table: Hoth Therapeutics Inc (HOTH) - SETE News
Hoth Therapeutics Inc (HOTH) gets rating Initiated from The Benchmark Company - Knox Daily
Hoth Therapeutics Inc [HOTH] Revenue clocked in at $0.00 million, down -25.69% YTD: What’s Next? - The DBT News
Balance Sheet Dive: Hoth Therapeutics Inc (HOTH)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Choreo LLC Purchases New Shares in The Hanover Insurance Group, Inc. (NYSE:THG) - Defense World
C4 Therapeutics Inc (NASDAQ: CCCC) Up 14.34% This Year: What To Expect Next - Stocks Register
Hoth Therapeutics Inc (HOTH) Stock: Navigating a Year of Volatility - The InvestChronicle
Hoth Therapeutics Shares Rally on Positive Alzheimer's Pre-clinical Study Data - MarketWatch
Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ - PR Newswire
Monopar Therapeutics' (MNPR) MNPR-101-Zr Shows Promising Tumor Targeting in Early Clinical Trial - BP Journal
Hoth Therapeutics Inc (HOTH) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Market Watch Highlights: Hoth Therapeutics Inc (HOTH) Ends on an Upturn Note at 1.12 - The Dwinnex
Hoth Therapeutics Inc [HOTH] Stock bought by Insider Knie Robb for $16750.0 - Knox Daily
AstraZeneca (NASDAQ: AZN) Stock Dips on Lung Cancer Drug Trial Setback - ABBO News
Relay Therapeutics Shows Promising Results with RLY-2608 in Breast Cancer Study - BP Journal
Aligos Therapeutics ($ALGS): A Bold Move to Regain Nasdaq Compliance - BP Journal
Hoth Therapeutics Inc: Rising -68.55% from 52-Week Low, Can the Stock Stay Afloat? - The InvestChronicle
Are Hoth Therapeutics Inc’shares a good deal? - US Post News
Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient - MSN
Hoth Therapeutics (NASDAQ: HOTH) Stock Skyrockets Following Approval of HT-001 Phase 2a Human Trials - ABBO News
Why Argan Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Benzinga
3.66%
1.11%
大文字化:
|
ボリューム (24 時間):